Victory For Takeda Abbott In Prostate Drug Patent Suit

Law360, New York (December 14, 2005, 12:00 AM EST) -- A jury has upheld a patent for a prostate cancer treatment held by Takeda Abbott Pharmaceuticals, marking a victory for the company in its litigation against pharmaceutical companies QLT Inc. and Sanofi-Synthelabo.

QLT said it plans to appeal the jury verdict.

TAP, a joint venture between Takeda Chemical Industries and Abbot Laboratories, filed the suit in 2003, alleging that the Eligard prostate cancer treatment controlled by all three defendants infringes a TAP patent.

Eligard was developed by Atrix Laboratories, which was purchased by QLT in November...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.